HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kazue Imai Selected Research

KT 90

11/2002Involvement of TNF-alpha changes in human cancer development, prevention and palliative care.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kazue Imai Research Topics

Disease

16Neoplasms (Cancer)
07/2013 - 11/2002
7Stomach Neoplasms (Stomach Cancer)
07/2013 - 11/2002
5Lung Neoplasms (Lung Cancer)
12/2009 - 11/2002
3Carcinoma (Carcinomatosis)
06/2009 - 11/2003
2Inflammation (Inflammations)
11/2012 - 12/2004
2Carcinogenesis
09/2008 - 11/2002
2Adenocarcinoma of Lung
06/2008 - 07/2006
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2008 - 08/2006
2Head and Neck Neoplasms (Head and Neck Cancer)
08/2006 - 07/2006
2Colorectal Neoplasms (Colorectal Cancer)
08/2006 - 07/2006
2Neoplasm Metastasis (Metastasis)
01/2005 - 05/2004
1Adenoma (Adenomas)
08/2012
1Experimental Melanoma
05/2012
1Graft vs Host Disease (Graft-Versus-Host Disease)
07/2010
1Adenocarcinoma
12/2009
1Esophageal Neoplasms (Esophageal Cancer)
07/2006
1Metaplasia
01/2005
1Hyperphagia (Overeating)
01/2005
1Breast Neoplasms (Breast Cancer)
11/2003
1Cardiovascular Diseases (Cardiovascular Disease)
01/2003

Drug/Important Bio-Agent (IBA)

5TeaIBA
08/2012 - 12/2002
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2012 - 11/2002
3Codon (Codons)IBA
02/2008 - 07/2006
2Interleukin-10 (Interleukin 10)IBA
07/2013 - 11/2012
2Biological ProductsIBA
08/2012 - 01/2005
2epigallocatechin gallate (epigallocatechin-3-gallate)IBA
05/2012 - 12/2002
2ErbB Receptors (EGF Receptor)IBA
12/2009 - 06/2008
2Transcription Factors (Transcription Factor)IBA
06/2009 - 01/2005
2Messenger RNA (mRNA)IBA
06/2008 - 01/2005
2Serine (L-Serine)FDA Link
08/2006 - 07/2006
2NucleotidesIBA
08/2005 - 11/2003
1Interleukin-4 (Interleukin 4)IBA
11/2012
1Interleukin-6 (Interleukin 6)IBA
11/2012
1CytokinesIBA
11/2012
1C-Reactive ProteinIBA
11/2012
1Immunoglobulins (Immunoglobulin)IBA
11/2012
1Reactive Oxygen Species (Oxygen Radicals)IBA
11/2012
1InterleukinsIBA
11/2012
1TabletsIBA
08/2012
1Cyclin-Dependent Kinase Inhibitor p16IBA
06/2009
1Estrogen ReceptorsIBA
06/2009
1Bone Morphogenetic Protein 2IBA
06/2009
1Calcium Channels (Calcium Channel)IBA
06/2009
1Mitogen-Activated Protein KinasesIBA
09/2008
1NF-kappa B (NF-kB)IBA
07/2008
1ChemokinesIBA
07/2008
1Gefitinib (Iressa)FDA Link
06/2008
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2008
1Tyrosine Kinase InhibitorsIBA
06/2008
1Glutamine (L-Glutamine)FDA Link
02/2008
1Arginine (L-Arginine)FDA Link
02/2008
1Proteins (Proteins, Gene)FDA Link
11/2007
1prolyl-proline (Pro-Pro)IBA
08/2006
1Proline (L-Proline)FDA Link
08/2006
1Alanine (L-Alanine)FDA Link
07/2006
1EnzymesIBA
07/2006
1DNA (Deoxyribonucleic Acid)IBA
01/2006
1arginylarginine (Arg-Arg)IBA
08/2005
1TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA
08/2005
1DecitabineFDA Link
01/2005
1Matrix Metalloproteinases (MMPs)IBA
01/2005
1Epidermal Growth Factor (EGF)IBA
01/2005
15' Untranslated Regions (5' UTR)IBA
01/2005
1Matrix Metalloproteinase 9 (Gelatinase B)IBA
01/2005
1Biomarkers (Surrogate Marker)IBA
12/2004
1Matrix Metalloproteinase 1 (Interstitial Collagenase)IBA
05/2004
1isoleucylvalineIBA
11/2003
1valylvaline (Val-Val)IBA
11/2003
1Pharmaceutical PreparationsIBA
12/2002
1Sulindac (Copal)FDA LinkGeneric
12/2002
1Analgesics (Analgesic Drugs)IBA
11/2002
1Membrane Proteins (Integral Membrane Proteins)IBA
11/2002
1Morphine (MS Contin)FDA LinkGeneric
11/2002
1Morphine DerivativesIBA
11/2002
1Protein Kinase CIBA
11/2002
1Cord FactorsIBA
11/2002
1TrehaloseIBA
11/2002
1KT 90IBA
11/2002

Therapy/Procedure

1Drug Therapy (Chemotherapy)
07/2010
1Radiotherapy
07/2010
1Palliative Care (Palliative Therapy)
11/2002